Your browser doesn't support javascript.
loading
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Siddharth, Sumit; Kuppusamy, Panjamurthy; Wu, Qitong; Nagalingam, Arumugam; Saxena, Neeraj K; Sharma, Dipali.
Affiliation
  • Siddharth S; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Kuppusamy P; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.
  • Wu Q; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Nagalingam A; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Saxena NK; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Sharma D; National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA.
Int J Mol Sci ; 23(15)2022 Jul 22.
Article in En | MEDLINE | ID: mdl-35897659
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms / Metformin / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals Language: En Journal: Int J Mol Sci Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms / Metformin / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals Language: En Journal: Int J Mol Sci Year: 2022 Type: Article Affiliation country: United States